Poolbeg Pharma (LON:POLB) Shares Down 6.4% – What’s Next?

Shares of Poolbeg Pharma PLC (LON:POLB) traded down 6.4% during mid-day trading on Monday . The company traded as low as GBX 7.60 and last traded at GBX 8.05. 3,195,051 shares traded hands during trading, an increase of 96% from the average session volume of 1,628,823 shares. The stock had previously closed at GBX 8.60.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Tuesday, May 26th.

Poolbeg Pharma Stock Performance

The company has a market cap of £56.76 million, a P/E ratio of -8.56 and a beta of 1.78. The company has a fifty day moving average price of GBX 4.93 and a two-hundred day moving average price of GBX 4.47.

Poolbeg Pharma (LON:POLB) last announced its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. Research analysts anticipate that Poolbeg Pharma PLC will post -0.68 EPS for the current year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.